Comments – Part of the growing trend for big pharma to secure bid data
sources for their own use. A move in the right direction towards ‘regulatory grade’ RWE.
READ TIME: 2 mins
*1. “Target RWE, which provides real-world evidence (RWE) solutions to the
pharmaceutical and biotech industries has acquired NoviSci Inc., a software
analytics and services company.” *
*2. “Related to this acquisition, Amgen Inc., a strategic investor in and
collaborator with NoviSci, has also made a strategic investment in the
combined company to fuel growth, joining existing Target RWE investors
Norwest Venture Partners and 22C Capital.” *
*3. “NoviSci technology combined with Target RWE’s will make it possible
for doctors, researchers, and others to find and use solid, scientifically
rigorous analysis in a relatively digestible form that automatically
updates as new information is available.” *
*4. “The acquisition significantly broadens Target RWE’s data analytics
capabilities and will enable the company to meet increasing demand for
high-quality evidence from real-world data, the companies said.” *
*5. “Target RWE designs custom data sets, analyses, and evidence to address
the complexities of healthcare evidence questions and quality
initiatives.” *
Source URL:
Biotech giant Amgen invests after Durham startups combine in healthcare data deal